Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Interrogating metabolic cross-talk in the tumour-bone microenvironment, new research from the Edwards Group shows how the pentose phosphate pathway contributes to prostate cancer bone metastasis.

Prostate cancer is the second leading cause of cancer-related death in men. While overall five-year survival rates for prostate cancer are 97.8%, in metastatic disease this falls to only 30%.

Once prostate cancer metastasises to bone, treatment options are limited and the malignancy becomes incurable. Prostate cancer cells are exquisitely dependent upon cellular interactions within the bone microenvironment to drive both tumour growth and survival and the development of the associated bone disease.

Research from Professor Claire Edwards’ team at the Botnar Research Centre, and published in Science Advances, identifies a new mechanism by which the bone microenvironment alters the energy requirements of prostate cancer cells to support disease progression. 

'The importance of cellular cross-talk within the tumour-bone microenvironment has long been recognised,' said Professor Edwards. 'In this study we show how bone cells alter the metabolic activity of prostate cancer cells.'

The first author of the study, Dr Jessica Whitburn, said: 'Through a collaboration with Professor Tomoyoshi Soga, Keio University, we used metabolomic profiling to identify changes in the pentose phosphate pathway. Genetic and pharmacologic manipulation of G6PD, the rate-limiting enzyme of this pathway, had a significant impact on prostate cancer cell growth, migration, metabolism and chemosensitivity. 

'The ability of cancer cells to reprogramme their cellular metabolism has recently been recognised as an additional hallmark of cancer. By understanding how the bone microenvironment drives the metabolic plasticity of prostate cancer cells, we reveal new mechanisms underlying disease pathogenesis and new metabolic targets for the treatment of prostate cancer bone metastasis.'

 

Blog posts

Marathon challenge for Prostate Cancer UK

Runners of all abilities started 2023 by challenging themselves to run 26.2 miles across January to fundraise for Prostate Cancer UK as part of the charity’s Run the Month: Marathon Edition.

Staff Census: We need you!

All Medical Sciences staff are invited to log into HR self-service and ensure their contact, diversity background and disability details are up to date. Between 6% and 27% of staff in the Division are missing their diversity data which makes it difficult to complete statutory reporting, understand or track our population changes and to plan actions around staff diversity and equality – make sure your data is complete today!

Oxford MedSci goes silver: 10 Years of Athena SWAN

The Medical Sciences Division is celebrating 10 years since its first Athena Swan bronze application, and the first year in which all 16 of its departments have achieved a silver award. The silver award recognises commitment to gender equality, understanding culture and context, and more. Read about our department’s hard work and innovation.